TD Cowen analyst Ritu Baral has maintained their bullish stance on OVID stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ritu Baral has given her Buy rating due to a combination of factors including Ovid Therapeutics’ promising pipeline and financial stability. The company is actively advancing its clinical trials, with significant data readouts expected in the coming years. For instance, the ongoing Phase 1 study of OV329 is anticipated to provide crucial safety and biomarker data by the third quarter of 2025, which will guide dose selection for future studies targeting treatment-resistant focal seizures.
Additionally, Ovid’s financial position appears robust, with a reported cash reserve of $43 million at the end of the first quarter of 2025, providing operational runway into the second half of 2026. This financial stability, coupled with the strategic development of their KCC2 activator programs, positions Ovid well for future growth. The planned proof-of-concept trial for OV4071 in conditions like Parkinson’s disease and Lewy body dementia further underscores the company’s potential to address unmet medical needs.